000161797 001__ 161797
000161797 005__ 20251017144639.0
000161797 0247_ $$2doi$$a10.1016/j.ctro.2025.100991
000161797 0248_ $$2sideral$$a144388
000161797 037__ $$aART-2025-144388
000161797 041__ $$aeng
000161797 100__ $$0(orcid)0000-0002-1530-5662$$aLozares, Sergio$$uUniversidad de Zaragoza
000161797 245__ $$aHead and neck and skin (HNS) GEC-ESTRO and BRAPHYQS working groups joint critical review of the use of Rhenium-188 in dermato-oncology
000161797 260__ $$c2025
000161797 5060_ $$aAccess copy available to the general public$$fUnrestricted
000161797 5203_ $$aNon-melanoma skin cancers are increasing globally, prompting the need for innovative, non-invasive treatment approaches. Radioactive rhenium (188Re) paste has emerged as an open-source radiation-based modality in dermato-oncology, offering a novel alternative to conventional radiotherapy and brachytherapy. In this review, a systematic literature search was conducted using PubMed, Scopus, Web of Science, and Google Scholar for studies published over the past 20 years. Data were extracted from case series, pilot studies, and clinical trials, with particular emphasis on response rates, dosimetric parameters, and treatment-associated toxicity. Findings from approximately 240 patients demonstrated complete response rates ranging from 86 % to 100 % after one or two treatment applications, while dosimetric analyses revealed a rapid dose fall-off that effectively confines the therapeutic effect to a tissue depth of 2–3 mm, with most adverse effects being mild and transient. Notably, 188Re differs from conventional brachytherapy (specifically high-dose-rate modality) due to its open-source application and unique dosimetric profile. The use of 188Re in clinical practice mandates a highly specialized, multidisciplinary team, including radiation oncologists, nuclear medicine specialists, and experienced medical physicists, and strict quality assurance protocols, thereby limiting its application to carefully selected cases. Although 188Re therapy offers a promising alternative for the treatment of superficial skin cancers, its distinct clinical and dosimetric characteristics warrant further randomized studies with extended follow-up to validate its efficacy and refine patient selection criteria under rigorous multidisciplinary oversight.
000161797 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
000161797 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000161797 700__ $$aTur, Paula
000161797 700__ $$aBallester, Facundo
000161797 700__ $$aBundschuh, Ralph Alexander
000161797 700__ $$aGonzález-Pérez, Víctor
000161797 700__ $$aJaberi, Ramin
000161797 700__ $$aVijande, Javier
000161797 700__ $$aWalter, Renate
000161797 700__ $$aTedgren, Åsa Carlsson
000161797 700__ $$aTagliaferri, Luca
000161797 700__ $$aSiebert, Frank-André
000161797 700__ $$aRembielak, Agata
000161797 7102_ $$11011$$2770$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Radiol. y Medicina Física
000161797 773__ $$g53 (2025), 100991 [9 pp.]$$tClinical and Translational Radiation Oncology$$x2405-6308
000161797 8564_ $$s1818500$$uhttps://zaguan.unizar.es/record/161797/files/texto_completo.pdf$$yVersión publicada
000161797 8564_ $$s2606802$$uhttps://zaguan.unizar.es/record/161797/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000161797 909CO $$ooai:zaguan.unizar.es:161797$$particulos$$pdriver
000161797 951__ $$a2025-10-17-14:31:08
000161797 980__ $$aARTICLE